This statistic shows the potential cumulative savings due to the introduction of biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020. Until 2017, assuming a price reduction of 20 percent for the 8 key products' biosimilars, savings would reach around 9 billion U.S. dollars.
Potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)*
Characteristic
20% price reduction
30% price reduction
40% price reduction
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Exclusive Premium Statistic
To access all Premium Statistics, you need a paid Statista Account
* Savings potential in EU5+US biosimilar accessible market dependent on change in price per treatment day. The accessible market analysis is based on Adalimumab, Insulin glargine, Etanercept, Infliximiab, Rituximab, Peg-filgrastim, Trastuzumab and Follitropin alpha. Savings potential in biosimilar accessible market at different price levels is calculated based on extrapolated size of the originator market between 2016 and 2020 based on historic CAGR and analogues. Accumulation of savings potential between 2016-2020 is shown.
EU-5 includes Germany, UK, France, Italy, and Spain.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Medicines for Europe. (September 8, 2016). Potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)* [Graph]. In Statista. Retrieved July 22, 2024, from https://www.statista.com/statistics/700008/potential-savings-due-to-biosimilars-in-eu5-and-us/
Medicines for Europe. "Potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)*." Chart. September 8, 2016. Statista. Accessed July 22, 2024. https://www.statista.com/statistics/700008/potential-savings-due-to-biosimilars-in-eu5-and-us/
Medicines for Europe. (2016). Potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)*. Statista. Statista Inc.. Accessed: July 22, 2024. https://www.statista.com/statistics/700008/potential-savings-due-to-biosimilars-in-eu5-and-us/
Medicines for Europe. "Potential Savings Due to Biosimilars for 8 Key Products Combined in Eu-5 Countries and The U.S. between 2016 and 2020 (in Billion Euros)*." Statista, Statista Inc., 8 Sep 2016, https://www.statista.com/statistics/700008/potential-savings-due-to-biosimilars-in-eu5-and-us/
Medicines for Europe, Potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)* Statista, https://www.statista.com/statistics/700008/potential-savings-due-to-biosimilars-in-eu5-and-us/ (last visited July 22, 2024)
Potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)* [Graph], Medicines for Europe, September 8, 2016. [Online]. Available: https://www.statista.com/statistics/700008/potential-savings-due-to-biosimilars-in-eu5-and-us/
